BSI-082 + Trastuzumab Deruxtecan for Cancer

This trial explores a new cancer treatment called BSI-082, both alone and in combination with another drug, to assess its impact on metastatic tumors. The trial consists of two parts: first, testing BSI-082 alone with gradually increasing doses; then, testing it with Trastuzumab Deruxtecan (T-DXd, an antibody-drug conjugate). The trial aims to assist patients with solid tumors that have returned, not responded to standard treatments, or have progressed after treatment. Individuals with confirmed advanced cancer that hasn't responded well to other therapies might be suitable candidates. As a Phase 1 trial, this research focuses on understanding the treatment's effects in people, offering participants the opportunity to be among the first to receive this new therapy.

The trial protocol does not specify if you need to stop taking your current medications. However, there is a requirement for a 4-week or 5 half-lives period without prior anticancer therapies before starting the trial.

Previous studies have tested BSI-082 for safety in people with cancer. Research shows that this treatment is being explored for its potential to help the immune system fight cancer cells. The FDA has approved BSI-082 for trials, indicating it has passed initial safety checks in the lab. Although detailed information on its side effects in humans is not yet available, FDA approval marks a positive step.

For the combination of BSI-082 with trastuzumab deruxtecan (T-DXd), research indicates that T-DXd is generally well-tolerated. Studies have confirmed its safety for treating HER2-positive cancers, with no unexpected side effects. This combination aims to enhance treatment effectiveness without introducing new risks.

Researchers are excited about BSI-082 because it offers a fresh approach to cancer treatment. Unlike traditional therapies, which often rely on chemotherapy or radiation, BSI-082 is a targeted therapy administered intravenously. It specifically aims at cancer cells, potentially reducing harm to healthy cells. Additionally, when combined with Trastuzumab Deruxtecan (T-DXd), it explores a dual-action approach that could enhance effectiveness. This innovative strategy might provide a more precise and potentially more effective treatment option for patients.

Research has shown that BSI-082 blocks the CD47-SIRPα signal, which cancer cells use to evade the immune system. By blocking this signal, the immune system can attack cancer more effectively. In animal studies, BSI-082 demonstrated strong effects against tumors, especially when combined with certain antibodies (proteins that attach to specific targets). Trastuzumab deruxtecan (T-DXd) has already proven very effective in treating certain types of breast cancer, yielding better results than other treatments. This trial will evaluate BSI-082 as a monotherapy in various doses and in combination with T-DXd. Together, BSI-082 and T-DXd may offer a powerful combination to combat advanced cancers.¹²⁴⁶⁷